My watch list
my.chemeurope.com  
Login  

Cediranib



Cediranib
Systematic (IUPAC) name
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-
7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
Identifiers
CAS number  ?
ATC code  ?
PubChem  ?
Chemical data
Formula C25H27FN4O3 
Mol. mass 450.5 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life 12 to 35 hours
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes Oral

Cediranib (tentative trade name Recentin), also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases. It is being developed by AstraZeneca as a possible chemotherapeutic agent for oral administration.

As of 2007, it is undergoing Phase I clinical trials for the treatment of non-small cell lung cancer and colorectal cancer in adults, as well as tumors of the central nervous system in children.

Further reading

  • Wedge S, Kendrew J, Hennequin L et al. (2005). "AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer". Cancer Res 65 (10): 4389–400. PMID 15899831.
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Cediranib". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE